Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

As the pharmaceutical industry continues to push the boundaries of innovation, the role of digital solutions like eCOA platforms will only grow in significance. For rare disease trials, where patient ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to ...

As wearable technologies continue to rapidly develop, the use cases for wearable devices evolve and expand. Artificial intelligence (AI) and machine learning (ML) drive these devices and the ...

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...